Compare AES Corp (AES) vs Ascendis Pharma A/S (ASND) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AES Corp vs Ascendis Pharma A/S — how do they compare? AES Corp trades at $14.64 (market cap $10.43B), while Ascendis Pharma A/S trades at $277.16 (market cap $17.51B). The key difference: Ascendis Pharma A/S is the larger of the two by market cap, and AES Corp pays a 4.81% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| AES | ASND | |
|---|---|---|
Market Cap | $10.43B | $17.51B |
Sector | Utilities | Health |
52-Week High | $17.28 | $274.50 |
52-Week Low | $11.07 | $163.32 |
Enterprise Value | $39.77B | $17.88B |
Dividend Yield | 4.81% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Ascendis Pharma (ASND) trades at $266.97, down 2.74% on the day. The stock maintains a bullish technical outlook with moving averages supporting the uptrend, though RSI levels suggest overbought conditions. Fundamentally, revenue growth is strong, reaching $720.13M in 2025, but the company remains unprofitable with a net loss of $228.03M. Recent positive clinical trial data for TransCon CNP and inclusion in Russell indexes highlight ongoing business momentum.
The outlook is optimistic, driven by analyst consensus and a $320 price target, but risks include persistent losses, high debt levels, and reliance on pipeline success. Near-term performance hinges on Q2 2026 earnings versus the $1.29 EPS expectation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AES Corp
AES is a global power company operating across 14 countries and 4 continents. Its current generation portfolio as of year-end 2021 consists of over 31 gigawatts of generation, with the generation mix composed of renewables (43%), gas (32%), coal (23%), and oil (2%). The company has 3.5 gigawatts of generation under construction. AES has majority ownership and operates six electric utilities distributing power to 2.6 million customers.
Read more on AES →About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →
